Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (NASDAQ: APYX) is a cutting-edge energy technology company that develops, manufactures, and markets advanced medical devices for the cosmetic and surgical markets globally. The company operates through two primary segments: Advanced Energy and Original Equipment Manufacturing (OEM).
Under the Renuvion brand, Apyx Medical offers proprietary helium plasma and radiofrequency technology, which is widely used in cosmetic surgery. This innovative technology provides surgeons with the ability to apply controlled heat to tissues, optimizing results in procedures such as body contouring and liposuction. The J-Plasma system, marketed for surgical applications within hospitals, minimizes unintended tissue trauma during surgical operations.
Recent achievements underline Apyx Medical's commitment to advancing medical technology. In the third quarter of 2023, the company reported a 31% year-over-year increase in total revenue, highlighted by a 39% increase in Advanced Energy sales. Significant strides were made in developing the Apyx One Generator and associated accessories, which have seen robust global demand.
From a financial perspective, Apyx Medical continues to strengthen its position. For the year ending December 31, 2023, the company secured a new five-year credit agreement with Perceptive Advisors, providing up to $45 million in capital. This new agreement enhances the company's financial flexibility and supports its growth strategy.
The company's OEM segment collaborates with other medical device manufacturers to design, develop, and produce electrosurgical generators and related accessories. This segment saw a 14% year-over-year growth in revenue during the first three quarters of 2023.
Apyx Medical remains focused on leveraging regulatory clearances and expanding its market reach. Noteworthy is its active participation in industry conferences, such as the American Academy of Cosmetic Surgery’s Annual Meeting, where it showcases its innovative products and clinical findings. The company continues to invest in research and development to enhance its product offerings, and is committed to maintaining rigorous safety and efficacy standards, supported by an extensive portfolio of clinical evidence.
In summary, Apyx Medical Corporation is at the forefront of medical energy technology, providing innovative solutions that elevate patient care in both cosmetic and surgical markets. With a robust financial outlook, strategic industry partnerships, and a continuous drive for product excellence, Apyx Medical is poised for sustained growth and market leadership.
Apyx Medical Corporation (NASDAQ: APYX) reported third-quarter 2022 results, revealing total revenue of $9.1 million, down 23% year-over-year. Advanced Energy revenue fell 31% to $7.1 million, while OEM revenue rose 34% to $2.0 million. The company recorded a net loss of $5.8 million, worsening from $4.2 million in Q3 2021. Due to ongoing disruptions from an FDA Safety Communication, Apyx revised its 2022 revenue guidance to a range of $44.8 million to $47.9 million, reflecting a potential decline of 8% to 1%. The management emphasized efforts to engage customers and secure new regulatory clearances.
Apyx Medical Corporation (NASDAQ:APYX) will release its third quarter financial results for fiscal year 2022 before the market opens on November 10th. A conference call, scheduled for 8:00 a.m. ET on the same day, will discuss the quarterly results and include a question and answer session. Interested participants can join via phone or listen to a live webcast through the company’s Investor Relations webpage. A replay of the call will be available for two weeks post-event.
Apyx Medical Corporation (NASDAQ: APYX) announced a new surgeon testimonial video featuring its Renuvion Helium Plasma Technology. Leading plastic surgeons, including Dr. Paul Nassif, attest to the device's effectiveness in achieving superior cosmetic results. Renuvion is FDA-cleared for improving lax skin on the neck and for specific dermatological procedures. Hundreds of physicians in the U.S. utilize this innovative technology in their practices, highlighting its safety and efficacy.
Apyx Medical Corporation (NASDAQ:APYX) has announced its participation in the Lake Street Best Ideas Growth Conference on September 14th at The Yale Club, New York, NY. Management will engage in one-on-one meetings, but there will not be a formal presentation. The company specializes in advanced energy technology, offering innovative helium plasma products such as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgeries. These technologies provide controlled heating for optimal surgical results.
Apyx Medical Corporation (NASDAQ: APYX) reported a second quarter 2022 revenue of $10.3 million, an 8% decrease year-over-year. Advanced Energy revenues fell 16% to $8.4 million, while OEM revenues rose 55% to $1.9 million. The net loss increased to $5.4 million from $4.0 million in Q2 2021. The company adjusted its full-year revenue guidance to $51.0 million to $56.4 million, reflecting a 5% to 16% growth expectation. Key 510(k) clearances from the FDA for Renuvion products were achieved, expanding market opportunities.
Apyx Medical Corporation (NASDAQ:APYX) has unveiled its inaugural environmental, social, and governance (ESG) data through a newly released tear sheet. This document, compiled with third-party assistance, highlights the Company's ESG priorities and sets a baseline for future assessments. It includes data for the year ending December 31, 2021, focusing on environmental, social, and governance issues, including energy management, product safety, and Board diversity. CEO Charlie Goodwin emphasized the importance of these efforts to positively impact employees and stakeholders.
Apyx Medical Corporation (NASDAQ: APYX) has received FDA 510(k) clearance for its Renuvion technology, enabling its use in cosmetic procedures aimed at improving lax skin in the neck and chin. Renuvion stands out as the only FDA-cleared solution for this application, providing a minimally-invasive option to address age-related skin sagging. The company anticipates a surge in demand in the cosmetic market, with Renuvion offering effective treatment by directly targeting collagen fibers for a smoother appearance. This development positions Apyx Medical favorably in the growing aesthetic medical field.
Apyx Medical Corporation (NASDAQ:APYX) announced FDA 510(k) clearance for its Renuvion APR Handpiece, allowing use in dermatological procedures for tightening lax skin in the neck and submental areas. This clearance positions Renuvion as the only FDA-cleared device for these applications, targeting an estimated 200,000 neck contouring procedures annually in the U.S. A limited launch is expected by Q3 2022, with full commercialization aimed for year-end. This marks the company's second regulatory clearance within two months, highlighting its commitment to innovative medical solutions.
Apyx Medical Corporation (NASDAQ:APYX) has released positive results from its pivotal Phase II study of the Renuvion device aimed at improving lax skin appearance in the neck and submental area. The study demonstrated key outcomes, with 82.5% of 65 subjects showing improvements at six months, and 96.9% reporting low pain levels post-procedure. Additionally, 85.5% of participants rated their results as improved. No serious adverse events were linked to Renuvion. The company anticipates moving forward with marketing efforts subject to FDA clearance.
Apyx Medical Corporation (NASDAQ:APYX) will release its financial results for Q2 fiscal 2022 on August 11th, after market close. A conference call is scheduled for 5:00 p.m. ET that day, where management will discuss the financial performance and answer questions. Participants can join via phone or a live webcast. Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Technology products marketed as Renuvion and J-Plasma, used for controlled tissue heating in surgical procedures.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
What does Apyx Medical Corporation specialize in?
What are the key product lines of Apyx Medical?
What recent financial achievements has Apyx Medical reported?
What significant recent projects has Apyx Medical undertaken?
Who are the typical customers for Apyx Medical's Renuvion technology?
What recent strategic financial move has Apyx Medical made?
How does Apyx Medical contribute to the OEM market?
What role does research and development play at Apyx Medical?
Where can I find more information about Apyx Medical's products?
What industry events does Apyx Medical participate in?
